Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes
Suxiang Chen1,2, Nabayet Sbuh1,2, Rakesh N Veedu1,2
1Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia.
Nucleic Acid Therapeutics
|October 7, 2020
Summary
Antisense oligonucleotides offer a novel approach to managing type 2 diabetes (T2D) by targeting disease-causing genes. This review explores their potential in treating hyperglycemia and insulin resistance.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Type 2 diabetes (T2D) is a chronic metabolic disorder marked by hyperglycemia due to insulin issues.
- Current treatments, like oral hypoglycemics, have limited efficacy and side effects, failing to halt disease progression.
- Antisense oligonucleotides (ASOs) show promise for T2D by downregulating disease-related gene expression.
Purpose of the Study:
- To comprehensively review antisense molecules developed for T2D treatment.
- To explore the potential of ASOs in suppressing genes linked to insulin resistance and hyperglycemia.
Main Methods:
- Literature review of antisense oligonucleotide research for T2D.
- Analysis of ASO mechanisms targeting disease-causing genes at RNA and protein levels.
- Examination of FDA-approved antisense agents for therapeutic applications.
Main Results:
- ASOs can effectively downregulate specific gene expression implicated in T2D.
- Seven ASO agents are currently FDA-approved for various human diseases.
- This approach offers a targeted strategy beyond conventional T2D therapies.
Conclusions:
- Antisense oligonucleotides represent a promising therapeutic strategy for T2D.
- Targeting gene expression offers a novel pathway for managing hyperglycemia and insulin resistance.
- Further research into ASOs could lead to advanced T2D prevention and treatment options.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
18.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
498
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
498
01:24Glucagon-like Receptor Agonists
670
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
670
01:17Oral Hypoglycemic Agents: Sulfonylureas
605
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
605
01:22Diabetes Mellitus: Overview and Type I Subtype
4.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.6K
01:22Diabetes Mellitus: Type 2 and Gestational
4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K